Kali Therapeutics is conducting a first-in-human early phase trial in participants with Rheumatoid Arthritis.
Objective: The study is investigating the safety and effectiveness of KT501 by a single subcutaneous administration in participants with Rheumatoid Arthritis (RA).
Duration: Approximately 24 participants in total with RA will be enrolled. All participants will receive a single dose of KT501 on Day 1 and followed up until Week 12. If necessary, based on participant immune cell lab results, additional follow-up for up to 48 weeks may be required.
Participant Profile: Adults aged 18-75 years old who have been diagnosed with RA for at least 6 months, who currently have moderate to severe RA and have had an inadequate response to available treatments (as defined in the protocol). Stable use of traditional DMARDs is permitted.
Location: Veritus Research, 855 Mountain Hwy, Bayswater VIC, Australia
Date: Enrollment is ongoing and will continue until enrollment is complete
Additional study information is available here: NCT07234773